Preoperative Localization of Infraclinical Breast Tumors: Isotopic Localization by iodine125 Seed Versus Standard Localization Using a Metal Wire

NCT ID: NCT02759133

Last Updated: 2023-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2023-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a monocentric, non-inferiority, randomized cohort study with an open 1:1 ratio comparing the impact of iodine seed tumor localization (arm B) vs. standard localization using a metal guide (arm A) on the quality of the surgical resection margins in parallel groups with an interim analysis in patients with breast cancer.

Randomization will be performed using histologic status stratification: in situ ductal /invasive lobular +/- an in situ component / invasive ductal +/- an in situ component.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The widespread development of organized breast cancer screening has enabled diagnosis of nonpalpable, small-size cancer lesions (infraclinical stage). When conservative breast surgery is scheduled (tumorectomy or zonectomy), preoperative localization of the lesion is mandatory. To date, wire localization of non-palpable lesions is the most frequently used technique worldwide.

Nevertheless, this technique presents a number of drawbacks:

* it is very uncomfortable for the patient. The wire is implanted transcutaneously, crosses the skin to reach the lesion and then protrudes outside the breast, thus limiting the patient's mobility and giving rise to discomfort and even pain during movement.
* furthermore, and for the same above-mention reasons, there is a risk of the wire becoming dislodged, breaking or being disinserted during patient movements (transfer between units, pre-op shower, installation in the operating room), thus jeopardizing the quality of the planned surgery by increasing the risk of unhealthy resection margins or even of non-removal of the tumor. Cases have even been reported of intrapulmonary wire migration.
* in order to lessen these risks, the wire must be placed as late as possible before transfer to the surgical wing (the previous day at the earliest). Consequently, organizing the patient's transfer, particularly in the event of outpatient surgery (less than 12h at the hospital) becomes complicated and requires coordination between the different units in charge of preoperative management (radiology, nuclear medicine, admittance, and operating room) and early inclusion of these patients in the operating room schedule or postponement of surgery in the event of migration or displacement of the wire. These various constraints can result in a reduction of the number of patients able to benefit from outpatient management, as demonstrated by Dravet et al. Several alternative techniques have been put forward in order to overcome these difficulties, including radioguided seed localization (RSL), which consists in implanting a sealed source of radioactive iodine125 (iodine seed) inside the tumor to provide a preoperative marker which can be monitored by the surgeon using a gamma probe. The RSL technique is currently used in Europe (Netherlands), Canada and the USA.

This technique appears to offer several advantages:

* It is a simple radiologic technique performed under ultrasound or stereotaxic control, allowing accurate localization of the lesion with no risk of the marker moving or being displaced,
* It requires no special training for surgeons already skilled in the use of gamma probes in the sentinel node technique,
* It allows concomitant, interference-free performance of sentinel node surgery by means of a gamma probe able to detect specifically Tc99m and/or Iodine 125,
* It is free of organizational localization constraints limiting access to outpatient surgery, which ranks as a high priority for our governing bodies (50% of all surgeries will be performed on an outpatient basis by 2016). As the half-life of iodine seeds is 60 days, it should be possible, in theory, to insert them several days, or even several months, before surgery. In this way, patient transfer is simplified and the turnover of the operating block for outpatient management can be increased. Moreover, this localization method could also be used for tumorectomies following neoadjuvant chemotherapy,
* It presents none of the drawbacks related to patient mobility. Patient comfort is enhanced and the patient is able to move freely, with fewer risks of displacement or disinsertion, and less pain, etc.
* Patient satisfaction is higher among those women who have undergone iodine seed localization as opposed to the conventional localization techniques

Furthermore, various studies have demonstrated the safety of this technique in terms of radiation protection as radiation is minimal to the patient (equivalent to the amount received from two mammography views) as well as to the staff. Its reliability regarding the surgical excision procedure (positive or inadequate margin rates, revision surgery rates) has been demonstrated in 3 randomized studies with a high level of evidence.

Thus, in 2001, Gray et al. published the first randomized study comparing the RSL technique with the conventional wire method and showed the superiority of iodine seed localization in terms of positive margin and surgical revision rates (RSL 26% vs WL 26%, p=0.02) with no concomitant increase in tumorectomy specimen volumes or marker migration rates. More recently, Lovrics et al. (2011) and Bloomquist et al (2015) published randomized non-inferiority studies highlighting the equivalent results between these two techniques regarding the quality of tumor excision (positive margins rates in: RSL 15.1% vs WL 19% p=0.389, and in: RSL 19.4% vs 15.3%, p=0.53). In addition, the RSL method showed a significant advantage regarding operating times and pain experienced by patients during the localization procedure.

No French team has investigated this localization method on account of legal constraints. Nonetheless, it would appear that the wire localization technique does not satisfy surgical teams since another pre-operative localization technique involving injection of Tc99m into contact with the tumor has been developed over the past few years to replace the wire method. This procedure has met with little success, and has been gradually abandoned. Unfortunately, injecting Tc99m around the tumor renders the surgical procedure less precise or necessitates resecting a large segment of the gland with potentially damaging esthetic repercussions. Implantation of a sealed radioactive source such as an iodine seed helps mitigate this drawback.

This study project aims to evaluate the feasibility and safety of using 1 grain of iodine for localization purposes by means of a randomized comparative study comparing wire localization with iodine seed localization in patients presenting an in situ, biopsy-proven, non-palpable invasive or ductal breast carcinoma requiring conservative surgical management associated, or not, with an axillary procedure (SN removal or axillary curettage).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A - A standard Localization technique

A standard Localization technique : Metal wire as localization technique for breast cancer surgery

Group Type ACTIVE_COMPARATOR

Metal wire

Intervention Type DEVICE

Localization technique for breast surgery using metal wire

B - Experimental Localization technique

Experimental Localization technique: Radioactive Iodine seed as localization technique for breast cancer surgery

Group Type EXPERIMENTAL

Radioactive Iodine Seed

Intervention Type DEVICE

Localization technique for breast surgery using Radioactive Iodine Seed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metal wire

Localization technique for breast surgery using metal wire

Intervention Type DEVICE

Radioactive Iodine Seed

Localization technique for breast surgery using Radioactive Iodine Seed

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

standard Localization technique Experimental Localization technique

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 or over
* Patients suffering from unifocal or in situ invasive or ductal breast cancer proven by anatomopathologic analysis (biopsy).
* Non-palpable tumor measuring at least 5 mm (minimum size deemed sufficient for the lesion to be visible by ultrasound) and ≤ 30 mm, visible by ultrasound and constituting a mass.
* Patients needing conservative first surgery management by preoperative tumor localization. For women of childbearing age, an effective contraceptive is mandatory throughout the study and up to 6 months post-operatively.
* Patients who have been made aware of the information sheet and have given their written signed informed consent.
* Patients benefitting from social health insurance coverage.

Exclusion Criteria

* Patients with a history of homolateral breast cancer.
* Patients who have undergone neoadjuvant chemotherapy.
* Multifocal or multicentric cancer.
* Metastatic breast cancer.
* Cancer presenting in the form of microcalcifications with no visible mass.
* Vulnerable patients: pregnant or breastfeeding women, women deprived of their freedom by administrative or judicial decree, adults subject to a legal protection order or unable to give their consent.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Antoine Lacassagne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emmanuel BARRANGER, phd

Role: PRINCIPAL_INVESTIGATOR

Centre Antoine Lacassagne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Antoine LACASSAGNE

Nice, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015/18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.